Liraglutide Phase III Diabetes Program Delayed Until 2005
This article was originally published in The Pink Sheet Daily
Novo Nordisk expects its glucagon-like peptide-1 analog liraglutide to enter Phase III trials in 2005
You may also be interested in...
The preclinical peptide hormone will likely be developed for Type-2 diabetes. Human Genome Sciences believes potential advantage with Albugon is prolonged half-life.
Long-term patient follow-up is extended to two years in light of regulatory concerns about PPAR class safety, firm tells analysts. News is setback for AstraZeneca's near-term cardiovascular pipeline and a boost for Bristol/Merck's muraglitazar.
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.